ES2556340T3 - Levaduras para el tratamiento de úlceras gástricas o intestinales inducidas por agentes gastrotóxicos - Google Patents

Levaduras para el tratamiento de úlceras gástricas o intestinales inducidas por agentes gastrotóxicos Download PDF

Info

Publication number
ES2556340T3
ES2556340T3 ES10194022.9T ES10194022T ES2556340T3 ES 2556340 T3 ES2556340 T3 ES 2556340T3 ES 10194022 T ES10194022 T ES 10194022T ES 2556340 T3 ES2556340 T3 ES 2556340T3
Authority
ES
Spain
Prior art keywords
gastric
treatment
gastrotoxic
yeasts
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10194022.9T
Other languages
English (en)
Inventor
Philippe Girard
Marie-Emmanuelle Le Guern
Marc Verleye
Bernard Hublot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocodex SAS
Original Assignee
Biocodex SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocodex SAS filed Critical Biocodex SAS
Application granted granted Critical
Publication of ES2556340T3 publication Critical patent/ES2556340T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Células de levadura para su utilización en la prevención o el tratamiento de las úlceras gástricas o intestinales inducidas por un principio activo de medicamento que tiene una actividad gastrotóxica y susceptible de provocar úlceras gástricas o intestinales como efecto secundario.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES10194022.9T 2009-12-08 2010-12-07 Levaduras para el tratamiento de úlceras gástricas o intestinales inducidas por agentes gastrotóxicos Active ES2556340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0958734A FR2953412B1 (fr) 2009-12-08 2009-12-08 Medicament pour le traitement des ulceres gastro-intestinaux
FR0958734 2009-12-08

Publications (1)

Publication Number Publication Date
ES2556340T3 true ES2556340T3 (es) 2016-01-15

Family

ID=42301615

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10194022.9T Active ES2556340T3 (es) 2009-12-08 2010-12-07 Levaduras para el tratamiento de úlceras gástricas o intestinales inducidas por agentes gastrotóxicos

Country Status (7)

Country Link
US (1) US9241961B2 (es)
EP (1) EP2332556B1 (es)
CA (1) CA2724937C (es)
ES (1) ES2556340T3 (es)
FR (1) FR2953412B1 (es)
PL (1) PL2332556T3 (es)
PT (1) PT2332556E (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278326A (zh) 2017-07-28 2020-06-12 轨迹Ip有限责任公司 改善皮肤、头发和头皮健康的基于酵母的面膜
EP3801463A4 (en) 2018-05-25 2022-05-04 Locus IP Company, LLC THERAPEUTIC COMPOSITIONS FOR IMPROVED HEALING OF WOUNDS AND SCARS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649383B1 (en) * 2002-06-28 2003-11-18 Ultra Biotech Limited Dietary supplements beneficial for the gastrointestinal system
AU2003274355A1 (en) * 2002-10-24 2004-05-13 Micap Plc. Targeted delivery
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
US20070298013A1 (en) * 2006-06-23 2007-12-27 Altman Jay A Animal Nutritional Supplement and Method

Also Published As

Publication number Publication date
FR2953412B1 (fr) 2012-04-20
EP2332556A1 (fr) 2011-06-15
CA2724937A1 (fr) 2011-06-08
FR2953412A1 (fr) 2011-06-10
PT2332556E (pt) 2016-01-22
PL2332556T3 (pl) 2016-05-31
CA2724937C (fr) 2020-05-26
US9241961B2 (en) 2016-01-26
US20110135616A1 (en) 2011-06-09
EP2332556B1 (fr) 2015-09-16

Similar Documents

Publication Publication Date Title
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
BRPI1007658A2 (pt) sistema de travesseiro ativo para manipular as condições de repouso de uma pessoa e método para manipular condições de repouso de uma pessoa
BR112014009418A2 (pt) macrociclos peptidomiméticos
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
MX2010006096A (es) Anticuerpo anti-nr10 y su uso.
CL2012002173A1 (es) Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.
CO6491052A2 (es) Compuestos espirociclicos que contienen notrogeno y su uso medicinal
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EP2419058A4 (en) STENTS WITH TAXED ELUTION
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
ES2571105T3 (es) Modulador
CO6480985A2 (es) Formulaciones para el tratamiento del dolor tisular profundo
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
MX2014006129A (es) Instalacion movil de tratamiento, diagnostico y cirugia menor.
AR086395A1 (es) Envase para el tratamiento de patologias
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
ES2633762T3 (es) Hipertensión e hiperuricemia
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento